As of Friday close, Ionis Pharmaceuticals Inc.’s (NASDAQ:IONS) stock was down -$0.28, moving down -0.72 percent to $38.85. The average number of shares traded per day over the past five days has been 726,040 shares. 2 times new highs have been achieved over the past 5 days, with a -$1.37 fall in that time frame. In the last twenty days, the average volume was 919,145, while in the previous 50 days, it was 1,153,218.
Since last month, IONS stock retreated -5.15%. Shares of the company fell to $38.26 on 07/27/23, the lowest level in the past month. A 52-week high of $48.82 was reached on 07/17/23 after having rallying from a 52-week low of $32.69. Since the beginning of this year, IONS’s stock price has risen by 2.86% or $1.08, and marked a new high 9 times. However, the stock has declined by -20.42% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
IONS stock investors should be aware that Ionis Pharmaceuticals Inc. (IONS) stock had its last reported insider trading activity 18 days ago on Aug 01. Diaz Allene M., the Director of the company, disposed of 657 shares for $41.05 on Aug 01. It resulted in a $26,970 divestment by the insider. KLEIN JOSEPH III sold 3,555 shares at an average price of $42.00 on Jul 18. The insider now owns 20,346 shares following the transaction. On Jul 07, Chief Executive Officer Monia Brett P sold 18,650 shares at $42.25 apiece. The transaction was valued at $787,953.
Valuation Metrics
The stock’s beta is 0.51. Besides these, the trailing price-to-sales (P/S) ratio of 8.73, the price-to-book (PB) ratio of 12.99.
Financial Health
In the three months ended June 29, Ionis Pharmaceuticals Inc.’s quick ratio stood at 9.00, while its current ratio was 9.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 3.07, and the total debt-to-equity ratio was 3.09. On the profitability front, the trailing twelve-month gross margin is 98.60% percent. In the year ended June 29, EBITDA margin amounted to -66.07%, whereas operating margins totaled -74.80%. Based on annual data, IONS earned $573.25 million in gross profit and brought in $587.37 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -24.00%. Return on equity (ROE) for the past 12 months was -59.40%.
In Ionis Pharmaceuticals Inc.’s quarter-end financial report for June 29, it reported total debt of $8.81 million against cash and short-term investments of $2.04 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. IONS’s revenue fell -237.12% to $178.56 million during the quarter, while net income inched up to $130.52 million. While analysts expected Ionis Pharmaceuticals Inc. to report -$0.9 quarterly earnings, the actual figure was -$0.6 per share, beating the consensus estimate by 33.30%. During the quarter, the company generated -$90.47 million in EBITDA. The liabilities of Ionis Pharmaceuticals Inc. were 2.54 billion at the end of its most recent quarter ended June 29, and its total debt was $1.49 billion. The value of shareholders’ equity is $143.33 million.
Technical Picture
This quick technical analysis looks at Ionis Pharmaceuticals Inc.’s (IONS) price momentum. With a historical volatility rate of 14.28%, the RSI 9-day stood at 36.59% on 18 August.
With respect to its five-day moving average, the current Ionis Pharmaceuticals Inc. price is down by -3.41% percent or -$1.37. At present, IONS shares trade -4.43% below its 20-day simple moving average and +15.21% percent above its 100-day simple moving average. However, the stock is currently trading approximately -4.19% below its SMA50 and -12.10% below its SMA200.
Stochastic coefficient K was 13.31% and Stochastic coefficient D was 27.13%, while ATR was 0.90. Given the Stochastic reading of 7.41% for the 14-day period, the RSI (14) reading has been calculated as 40.80%. As of today, the MACD Oscillator reading stands at -0.49, while the 14-day reading stands at -0.60.
Analyst Ratings
Citigroup upgraded its rating on Ionis Pharmaceuticals Inc. (NASDAQ: IONS) to a Buy in a note to investors on July 31, 2023. The analysts firm previously had a Neutral rating on the stock.Ionis Pharmaceuticals Inc. (IONS) has been rated Overweight by analysts. According to 2 brokerage firms, IONS is a sell, and 6 firms recommend it is a Hold. There are 2 analysts who say the stock is underweight. A total of 1 analyst rate Ionis Pharmaceuticals Inc. stock as buy, with 11 recommending it as overweight.
With a median target price of $58.00, the current consensus forecast for the stock is $25.00 – $88.00. Based on these forecasts, analysts predict Ionis Pharmaceuticals Inc. (IONS) will achieve an average price target of $50.48.
